Important Safety Information Do not use AOD-9604 if you: Have active cancer or malignancy (use only under medical supervision with appropriate monitoring) Are pregnant or breastfeeding (safety data lacking in these populations) Have known allergy to growth hormone fragments or peptide compounds Have severe uncontrolled metabolic or cardiovascular disease without medical supervision Common side effects may include: Injection site reactions (mild redness, swelling, or tenderness), occasional mild headaches during initial use, and transient lightheadedness
Customized Plans: We tailor each program to meet your specific needs and health goals
GLP-1 drugs dominate the conversation on weight loss today
D 66 , 1221 (2010) Savage, E
The most popular study on Wegovy for obesity is the STEP 1 Trial, a large randomized control trial with about 1900 participants that examined how effective Wegovy (semaglutide) was at treating obesity in non-diabetic patients (3)
PlexusDx's personalized approach includes assessment of these behavioral and environmental factors alongside genetic data to create a comprehensive treatment plan